In order to reconcile our kinetic and binding results suggesting that a cancer-associated, activated mTOR mutant shows increased DEPTOR association, with previous results showing a decrease in the amount of DEPTOR co-immunoprecipitated with exogenously expressed mutant mTOR, we examined the effect of sustained mTORC1 activity on the association of DEPTOR with mTORC1. The gene discussed is MTOR; the disease is cancer.